Send to

Choose Destination
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Author information

Kaiser Permanente Washington Health Research Institute, Seattle.
University of Iowa, Iowa City.
Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
Stanford University, Stanford, California.
University of California, San Francisco.
Oregon Health & Science University, Portland.
Columbia University, New York, New York.
University of Pennsylvania, Philadelphia.
University of Georgia, Athens.
Virginia Tech Carilion School of Medicine, Roanoke.
Nationwide Children's Hospital, Columbus, Ohio.
Fairfax Family Practice Residency, Fairfax, Virginia.
Virginia Commonwealth University, Richmond.
Temple University, Philadelphia, Pennsylvania.
University of Alabama at Birmingham.
University of California, Los Angeles.
Boston University, Boston, Massachusetts.
Northwestern University, Evanston, Illinois.
Icahn School of Medicine at Mount Sinai, New York, New York.
James J. Peters Veterans Affairs Medical Center, Bronx, New York.
University of Hawaii, Honolulu.
Pacific Health Research and Education Institute, Honolulu, Hawaii.



In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men.


To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.

Evidence Review:

The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening. The reviews also examined the benefits and harms of PSA-based screening in patient subpopulations at higher risk of prostate cancer, including older men, African American men, and men with a family history of prostate cancer.


Adequate evidence from randomized clinical trials shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. Potential harms of screening include frequent false-positive results and psychological harms. Harms of prostate cancer treatment include erectile dysfunction, urinary incontinence, and bowel symptoms. About 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and 2 in 3 men will experience long-term erectile dysfunction. Adequate evidence shows that the harms of screening in men older than 70 years are at least moderate and greater than in younger men because of increased risk of false-positive results, diagnostic harms from biopsies, and harms from treatment. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small. The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms.

Conclusions and Recommendation:

For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. (C recommendation) The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. (D recommendation).

Summary for patients in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center